Scott M. Damrauer

Scott M. Damrauer

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Scott M. Damrauer

Corporal Michael Crescenz VA Medical Center, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
FDFrederick E. Dewey
Frederick E. Dewey
VGViktoria Gusarova
Viktoria Gusarova
RDRichard L. Dunbar
Richard L. Dunbar
COColm O’dUshlaine
Colm O’dUshlaine
CSClaudia Schurmann
Claudia Schurmann
ABAris Baras
Aris Baras
Loss-of-function variants in the angiopoietin-like 3 gene (ANGPTL3) have been associated with decreased plasma levels of triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. It is not known whether such variants or therapeutic antagonism of ANGPTL3 are associated with a reduced risk of atherosclerotic cardiovascular disease. We sequenced the exons of ANGPTL3 in 58,335 participants in the DiscovEHR human genetics study. We performed tests of association for loss-of-function variants in ANGPTL3 with lipid levels and with coronary artery disease in 13,102 case patients and 40,430 controls from the DiscovEHR study, with follow-up studies involving 23,317 case patients and 107,166 controls from four population studies. We also tested the effects of a human monoclonal antibody, evinacumab, against Angptl3 in dyslipidemic mice and against ANGPTL3 in healthy human volunteers with elevated levels of triglycerides or LDL cholesterol. In the DiscovEHR study, participants with heterozygous loss-of-function variants in ANGPTL3 had significantly lower serum levels of triglycerides, HDL cholesterol, and LDL cholesterol than participants without these variants. Loss-of-function variants were found in 0.33% of case patients with coronary artery disease and in 0.45% of controls (adjusted odds ratio, 0.59; 95% confidence interval, 0.41 to 0.85; P=0.004). These results were confirmed in the follow-up studies. In dyslipidemic mice, inhibition of Angptl3 with evinacumab resulted in a greater decrease in atherosclerotic lesion area and necrotic content than a control antibody. In humans, evinacumab caused a dose-dependent placebo-adjusted reduction in fasting triglyceride levels of up to 76% and LDL cholesterol levels of up to 23%. Genetic and therapeutic antagonism of ANGPTL3 in humans and of Angptl3 in mice was associated with decreased levels of all three major lipid fractions and decreased odds of atherosclerotic cardiovascular disease. (Funded by Regeneron Pharmaceuticals and others; ClinicalTrials.gov number, NCT01749878.)

22 March 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
Noura Abul-HusnNoura Abul-Husn
Noura Abul-Husn
XCXiping Cheng
Xiping Cheng
ALAlexander H. Li
Alexander H. Li
YXYurong Xin
Yurong Xin
CSClaudia Schurmann
Claudia Schurmann
FDFrederick E. Dewey
Frederick E. Dewey
Elucidation of the genetic factors underlying chronic liver disease may reveal new therapeutic targets. We used exome sequence data and electronic health records from 46,544 participants in the DiscovEHR human genetics study to identify genetic variants associated with serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Variants that were replicated in three additional cohorts (12,527 persons) were evaluated for association with clinical diagnoses of chronic liver disease in DiscovEHR study participants and two independent cohorts (total of 37,173 persons) and with histopathological severity of liver disease in 2391 human liver samples. A splice variant (rs72613567:TA) in HSD17B13, encoding the hepatic lipid droplet protein hydroxysteroid 17-beta dehydrogenase 13, was found to be associated with reduced levels of ALT (P=4.2×10−12) and AST (P=6.2×10−10). Among DiscovEHR study participants, this variant was found to be associated with a reduced risk of alcoholic liver disease (by 42% [95% confidence interval {CI}, 20 to 58] among heterozygotes and by 53% [95% CI, 3 to 77] among homozygotes), nonalcoholic liver disease (by 17% [95% CI, 8 to 25] among heterozygotes and by 30% [95% CI, 13 to 43] among homozygotes), alcoholic cirrhosis (by 42% [95% CI, 14 to 61] among heterozygotes and by 73% [95% CI, 15 to 91] among homozygotes), and nonalcoholic cirrhosis (by 26% [95% CI, 7 to 40] among heterozygotes and by 49% [95% CI, 15 to 69] among homozygotes). Associations were confirmed in two independent cohorts. The rs72613567:TA variant was associated with a reduced risk of nonalcoholic steatohepatitis, but not steatosis, in human liver samples. The rs72613567:TA variant mitigated liver injury associated with the risk-increasing PNPLA3 p.I148M allele and resulted in an unstable and truncated protein with reduced enzymatic activity. A loss-of-function variant in HSD17B13 is associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis. (Funded by Regeneron Pharmaceuticals and others.)

11 June 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
CRCarolina Roselli
Carolina Roselli
MCMark D. Chaffin
Mark D. Chaffin
LWLu-Chen Weng
Lu-Chen Weng
SAStefanie Aeschbacher
Stefanie Aeschbacher
GAGustav Ahlberg
Gustav Ahlberg
PEPatrick T. Ellinor
Patrick T. Ellinor

15 June 2020 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MVMarijana Vujkovic
Marijana Vujkovic
JKJacob M. Keaton
Jacob M. Keaton
JLJulie A Lynch
Julie A Lynch
DMDonald R. Miller
Donald R. Miller
JZJin Zhou
Jin Zhou
DSDanish Saleheen
Danish Saleheen
We investigated type 2 diabetes (T2D) genetic susceptibility via multi-ancestry meta-analysis of 228,499 cases and 1,178,783 controls in the Million Veteran Program (MVP), DIAMANTE, Biobank Japan and other studies. We report 568 associations, including 286 autosomal, 7 X-chromosomal and 25 identified in ancestry-specific analyses that were previously unreported. Transcriptome-wide association analysis detected 3,568 T2D associations with genetically predicted gene expression in 687 novel genes; of these, 54 are known to interact with FDA-approved drugs. A polygenic risk score (PRS) was strongly associated with increased risk of T2D-related retinopathy and modestly associated with chronic kidney disease (CKD), peripheral artery disease (PAD) and neuropathy. We investigated the genetic etiology of T2D-related vascular outcomes in the MVP and observed statistical SNP–T2D interactions at 13 variants, including coronary heart disease (CHD), CKD, PAD and neuropathy. These findings may help to identify potential therapeutic targets for T2D and genomic pathways that link T2D to vascular outcomes.

19 July 2024 in Science
Verified
Journal Article
Open access
AVAnurag Verma
Anurag Verma
JHJennifer E. Huffman
Jennifer E. Huffman
ARAlex Rodriguez
Alex Rodriguez
MCMitchell Conery
Mitchell Conery
Molei LiuMolei Liu
Molei Liu
KLKatherine P. Liao
Katherine P. Liao
One of the justifiable criticisms of human genetic studies is the underrepresentation of participants from diverse populations. Lack of inclusion must be addressed at-scale to identify causal disease factors and understand the genetic causes of health disparities. We present genome-wide associations for 2068 traits from 635,969 participants in the Department of Veterans Affairs Million Veteran Program, a longitudinal study of diverse United States Veterans. Systematic analysis revealed 13,672 genomic risk loci; 1608 were only significant after including non-European populations. Fine-mapping identified causal variants at 6318 signals across 613 traits. One-third ( n = 2069) were identified in participants from non-European populations. This reveals a broadly similar genetic architecture across populations, highlights genetic insights gained from underrepresented groups, and presents an extensive atlas of genetic associations.

1 October 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
GCGlobal Lipids Genetics Consortium
Global Lipids Genetics Consortium
DKDerek Klarin
Derek Klarin
MCMyocardial Infarction Genetics (MIGen) Consortium
Myocardial Infarction Genetics (MIGen) Consortium
TCThe Geisinger-Regeneron DiscovEHR Collaboration
The Geisinger-Regeneron DiscovEHR Collaboration
TPThe Va Million Veteran Program
The Va Million Veteran Program
TAThemistocles L. Assimes
Themistocles L. Assimes